Project Grant K01AI193071
- This $162,000 Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) supports research to characterize the role of plasmacytoid dendritic cells (PDCs) in Mycobacterium tuberculosis (MTB) infection. The research aims to quantify PDC trafficking and activation in the lungs during MTB infection, and determine how PDC-driven type I interferon responses impact MTB control. The project will leverage a mouse model that...
- This $450,500 Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) to the University of Arkansas for Medical Sciences (UAMS) aims to enhance the understanding of macrophage subsets in tuberculosis (TB) infection and lesion biology. The project will leverage the C3HeB/FeJ mouse model, which forms the caseous necrotic lesions observed in human TB, to investigate how different lung macrophage subsets influence...
- This Project Grant award of $104,262, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to explore the relationship between genetic variants, transcriptional responses, and tuberculosis (TB) infection outcomes in macrophages derived from genetically diverse mice. The project aims to understand the basis for variability in TB infection outcomes, which may help identify ways to...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $832,076 Project Grant under the Allergy and Infectious Diseases Research federal grant program (CFDA 93.855) to the University of Massachusetts Medical School (UMMS) to conduct research on protective CD8 T cell responses to tuberculosis (TB). The research aims to characterize how vaccine-elicited CD8 T cells respond to Mycobacterium tuberculosis (MTB) challenge, identify protective antigens recognized by CD8 T cells,...
- This federal Project Grant award of $743,817 from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to delineate T cell receptor (TCR) families associated with protection from progression to pulmonary tuberculosis (TB) disease. The research will use advanced imaging techniques like fluorodeoxyglucose positron emission tomography and computed tomography (FDG PET-CT) to identify TB-exposed household...
- This $193,375 Project Grant, awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to identify bacterial determinants that may contribute to variable treatment responses for tuberculosis (TB). The project, conducted by researchers at the Harvard T.H. Chan School of Public Health, aims to investigate the effects of clinically prevalent variants in the ESX1 secretion system on TB...
- The University of Washington received a $188,760 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research (CFDA 93.855) program. The grant supports research to investigate the role of the lung inflammatory environment and cellular milieu in controlling Mycobacterium tuberculosis (MTB) infection and preventing tuberculosis (TB) disease. Specifically, the research will test the hypothesis that interferon gamma-activated...
- This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $2,863,501 in funding to the Regents of the University of Minnesota to conduct research on the mechanisms of CD4 T cell help to myeloid cells in tuberculosis (TB) infection. The award aims to define how CD4 T cell-derived effector functions drive myeloid cell activation and contribute to protective immunity...
- This $194,940 Project Grant was awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) with a start date of August 12, 2025 and an ultimate completion date of July 31, 2030. The primary goal of this research project is to discover the global human genetic regulators, including genes and genetic variants, that control macrophage antimicrobial responses to Mycobacterium tuberculosis (MTB) infection....
- The University of Washington received a $147,486 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The grant supports research to investigate the role of gamma delta (GD) T cells in controlling Mycobacterium tuberculosis (MTB) infection, which causes tuberculosis (TB). Key objectives include: Evaluating the molecular mechanisms underlying VD1 T cell recognition of mycobacterial...
This $209,408 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research (CFDA 93.855) program, supports a research project to characterize the role of unconventional T cell subsets in the immune response to Mycobacterium tuberculosis (MTB) infection using a non-human primate model. The goal is to gain a better understanding of these niche T cell populations in the lung granulomas during the early stages of MTB infection, which could inform future vaccine design. The project will be conducted by researchers at the University of Pittsburgh over a period of approximately 5 years, from September 2025 to August 2030. The findings from this work are expected to build on previous transgenic rodent studies and provide more relevant insights compared to human peripheral blood analysis, thereby advancing the development of improved tuberculosis vaccines.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $209.4k | 9/18/25 |